Skip to content
Photo of Audra Moran, Ovarian Cancer Research Alliance's President & CEO, with text overlay that reads Crains New York Business Notable Leader in Health Care

Ovarian Cancer Research Alliance

OCRA President & CEO Audra Moran Named Crain’s Notable Leader in Health Care

Under Moran’s leadership, OCRA has significantly expanded its efforts to fight ovarian and gynecologic cancer through innovative research, comprehensive support programs, and advocacy.

Read more

Only OCRA combines a laser focus with a panoramic view.

Funding Breakthrough Research

OCRA has invested $140 million toward finding a cure for ovarian and gynecologic cancers.

Discover our research

Supporting You Every Step of The Way

OCRA’s groundbreaking programs help 140,000 people each year navigate an overwhelming diagnosis, aiding patients and families when they need it most.

Find support

Advocacy is the Lifeblood of Change

OCRA advocates on Capitol Hill to improve research and education, drug and diagnostic safety, and access to quality care for all members of the ovarian and gynecologic cancer community. To date, OCRA has helped secure more than $3.8 billion in federal funding.

Take action now
A woman wearing sunglasses and a gray shirt kisses a small child on the lips. The child, dressed in a yellow shirt with a Disney character and a yellow bow in her hair, looks content. They are outdoors with trees and greenery in the background.

Genetic testing can save your life.

Knowledge is power. Genetic testing can lower your risk of ovarian and gynecologic cancers.

Find out more

The power of shared experiences

Join our Staying Connected Support Series, Woman to Woman Peer Mentor Program, or online community for knowledge, connection, support, and hope.

Find support

A Message from President and CEO Audra Moran

Get Involved

Join us as we drive innovation, offer hope, and invest in groundbreaking research that saves lives.

There are so many ways to lend a hand and improve the lives of thousands of ovarian and gynecologic cancer patients and their families.

Get involved

News & Updates

OCRA’s Spring Advocacy Day Brings Impact to Capitol Hill

OCRA’s Spring Advocacy Day Brings Impact to Capitol Hill

On March 17, 122 Advocate Leaders from nearly 40 states and Washington, DC, converged on Capitol Hill for OCRA’s Spring Advocacy Day. Together, they held 158 meetings with Congressional offices, carrying a clear message: Congress must sustain and build on its commitment to ovarian and gynecologic cancer research. The energy and reach of this year’s … Continued

Read more

FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer

FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer

On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab).  The approval follows last month’s FDA … Continued

Read more

The Overview: March 2026

The Overview: March 2026

OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued

Read more

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.